The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
ST03: A randomized trial of perioperative epirubicin, cisplatin plus capecitabine (ECX) with or without bevacizumab (B) in patients (pts) with operable gastric, esophagogastric junction (OGJ), or lower esophageal adenocarcinoma.
Elizabeth Catherine Smyth
No relevant relationships to disclose
Ruth E. Langley
Research Funding - Medical Resarch Council
Sally P. Stenning
Research Funding - Medical Research Council
Laura Stevenson
Research Funding - Medical Research Council
Claire Robb
Research Funding - Medical Research Council
William H. Allum
No relevant relationships to disclose
Heike Grabsch
No relevant relationships to disclose
Derek Alderson
No relevant relationships to disclose
Angela M. Riddell
No relevant relationships to disclose
Thomas Crosby
No relevant relationships to disclose
Robert Mason
No relevant relationships to disclose
Michael Griffin
No relevant relationships to disclose
Wasat Mansoor
No relevant relationships to disclose
Fareeda Y. Coxon
No relevant relationships to disclose
Stephen Falk
No relevant relationships to disclose
Debra Furniss
No relevant relationships to disclose
Gary William Middleton
No relevant relationships to disclose
Katherine Anne Sumpter
Other Remuneration - Roche
Jane M. Blazeby
No relevant relationships to disclose
David Cunningham
Consultant or Advisory Role - Amgen (U); Roche (U)
Research Funding - Amgen; Celgene; Merck Serono; Novartis; Roche; Sanofi